This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.brat.2010.10.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Peripheral T-cell lymphoma: From biology to practice to the future.
Cancer Treat Rev
September 2024
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:
Recent advancements in comprehending peripheral T-cell lymphomas (PTCLs) validate and broaden our perspective, highlighting their diverse nature and the varying molecular mechanisms underlying the entities. Based on a comprehensive accumulated understanding, the PTCLs currently overcome the most challenging features of any disease: rarity, incredible heterogeneity, and a lack of any established standard of care. The treatments deployed in the front-line are extrapolated from regimens developed for other diseases.
View Article and Find Full Text PDFOncology's trial and error: Analysis of the FDA withdrawn accelerated approvals.
Life Sci
June 2024
Massachusetts College or Pharmacy and Health Sciences, Boston, MA 02115, United States of America. Electronic address:
Launched in 1992, the FDA accelerated approval program grants drugs indicated in rare/life threatening diseases the ability to be marketed at a faster pace than through the traditional track. Each manufacturing company presents its drug to the FDA, and within 60 days it will determine if the drug is eligible for this path. Many drugs that were initially approved through this route, subsequently did not demonstrate their clinical benefits.
View Article and Find Full Text PDFMetastable precipitation and ion-extractant transport in liquid-liquid separations of trivalent elements.
Proc Natl Acad Sci U S A
March 2024
Department of Physics, University of Illinois at Chicago, Chicago, IL 60607.
The extractant-assisted transport of metal ions from aqueous to organic environments by liquid-liquid extraction has been widely used to separate and recover critical elements on an industrial scale. While current efforts focus on designing better extractants and optimizing process conditions, the mechanism that underlies ionic transport remains poorly understood. Here, we report a nonequilibrium process in the bulk aqueous phase that influences interfacial ion transport: the formation of metastable ion-extractant precipitates away from the liquid-liquid interface, separated from it by a depletion region without precipitates.
View Article and Find Full Text PDFAlzheimer's disease and clinical trials.
J Basic Clin Physiol Pharmacol
January 2024
Department of Pharmacology, 621320 College of Pharmacy JSS Academy of Technical Education, Noida, Uttar Pradesh, India.
Article Synopsis
- Alzheimer's disease (AD) is increasingly affecting a large global population, with many genetic factors associated with its progression.
- Despite numerous clinical trials aimed at developing effective treatments, many have failed due to various limitations and confounding factors related to specific drug candidates like thiethylperazine and crenezumab.
- The review aims to analyze these challenges in drug trial outcomes, suggesting that better preliminary assessments could prevent wasted resources in future clinical studies.
Youth patterns of use of electronic nicotine delivery systems (ENDS), Population Assessment of Tobacco and Health (PATH) waves 4-5.5.
Addict Behav
October 2023
PinneyAssociates, Inc., Pittsburgh, PA, United States.
Introduction: Youth use of electronic nicotine delivery systems (ENDS) is a continuing concern, making it important to assess evolving patterns, especially as non-tobacco, non-menthol (NTM) flavors were withdrawn for pod-based (but not disposable) ENDS in February 2020.
Methods: Trends in past-30-day (P30D) ENDS use and smoking prevalence, usual device type, flavor (tobacco, mint/menthol, or fruit/sweet/other), and regular/last-used brand in PATH Waves 4 (2017), 4.5 (2018), 5 (2019), and 5.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!